Outlook Therapeutics, Inc. (OTLK) Stock Forecast
OTLK analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 4 analysts
- Price target
- $5.03 average of analyst targets
- Upside to target
- +929.7% from the latest close
- Next earnings
- —
- 52-week range
- $0.20 – $2.47
OTLK analyst ratings
4 analystsNumber of analysts at each rating.
OTLK price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OTLK earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.05 | −$0.08 | −$0.01 | −$0.22 | +78.8% | 3 |
| Current fiscal year (FY2026) | −$0.43 | −$0.45 | −$0.42 | −$1.89 | +77.0% | 2 |
| Next fiscal year (FY2027) | −$0.12 | −$0.27 | −$0.03 | −$0.43 | +72.4% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OTLK revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $5.3M | $1.3M | $8.9M | +539.1% | 4 |
| Current fiscal year (FY2026) | $682,670 | −$100,000 | $1.7M | −51.7% | 3 |
| Next fiscal year (FY2027) | $44.1M | $30.0M | $74.7M | +6,355.6% | 4 |
OTLK EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OTLK revenue: reported and forecast
OTLK EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.07 | −$0.07 | −$0.05 | −$0.05 | −$0.05 | −37.7% | 1 up · 0 down |
| Current fiscal year (FY2026) | −$0.51 | −$0.51 | −$0.49 | −$0.42 | −$0.43 | −14.7% | 2 up · 0 down |
| Next fiscal year (FY2027) | −$0.22 | −$0.22 | −$0.16 | −$0.14 | −$0.12 | −45.5% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OTLK earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; OTLK beat in 6 of 12.
What analysts expect from OTLK
4 analysts cover Outlook Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.03, 929.7% above the latest close of $0.49. Analysts expect earnings of −$0.43 per share for FY2026, +77.0% from a year earlier. For FY2027 the average estimate is −$0.12 per share on revenue of $44.1 million. Outlook Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: OTLK income statement, OTLK key metrics, OTLK chart. See the OTLK stock overview for the latest quote and news.
OTLK forecast FAQ
What is Outlook Therapeutics's price target?
The average analyst price target for Outlook Therapeutics is $5.03, 929.7% above the latest close of $0.49.
Is Outlook Therapeutics a buy, hold or sell?
Of 4 analysts covering Outlook Therapeutics, 3 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Outlook Therapeutics's EPS forecast?
Analysts forecast −$0.43 per share for FY2026 (range −$0.45 to −$0.42); for FY2027 the estimate is −$0.12.
What is Outlook Therapeutics's revenue forecast?
The average revenue estimate for FY2026 is $0.7 million, growth of −51.7%; for FY2027 it is $44.1 million.
Does Outlook Therapeutics usually beat earnings estimates?
Outlook Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.